glp-1 agonists: Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Agonists Market Exclusive Research

If patients present with [NAION], they should be discontinued from the medicine immediately, and their whole healthcare team should be consulted.

It is important to note that following the cessation of treatment at week 26 and again at the end of the weaning treatment administration there was a slight increase in weight in both the cagrilintide and the liraglutide groups

Long-term metabolic health can be followed by the endocrinologists

Louis, United States Zaiyong Zheng, Southwest Medical University, China Updates Copyright 2025 Gong, Li, Shi, Wang, Dai, Chen and Su

10.12435/j.issn.2095-5227.2023.002 70 LiX.TaoF.PeiT.YouH.LiuY.GaoY